Expecting First Results From Phase 1 Clinical Trials Of COVID-19 Vaccine In October
CureVac shares have been under selling pressure and fell ~20% in September. For the same period shares of key rivals Moderna and BioNTech rose 7%...
329 Views
How High Can CureVac Stock Go After Blockbuster IPO? We Update Bull Case Scenario to $80 Per Share
CureVac stock closed at $55.90 per share during the first trading day, the best performance among biotech IPOs this year. Since the beginning of...
572 Views
CureVac IPO. Beating Rivals to Secure a COVID-19 Vaccine Based on MRNA Technology
German global clinical-stage biotech company and coronavirus vaccine developer CureVac set terms for $200M+ IPO (~13.3 million shares) at a...
506 Views
Lonza: A Bellwether Biopharma Focused CDMO | At Inflection Point, To Benefit from Ongoing Capex
Over the next few weeks/months, we will be initiating coverage on a few key players in the Global CDMO space, where we see interesting growth...
440 Views
U.S. Equity Strategy: Several Indicators Suggest a Pullback Likely
Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight...
435 Views